Back to Search Start Over

Towards a cancer mission in Horizon Europe: recommendations

Authors :
Kathi Apostolidis
Alexander M.M. Eggermont
Simon Oberst
Hans-Olov Adami
Fabien Calvo
Carlos Caldas
Ulrik Ringborg
Thierry Philip
Nancy Abou-Zeid
Josep Tabernero
Gerd Nettekoven
Francesco De Lorenzo
Neil K. Aaronson
Richard Price
Michael Baumann
Sakari Karjalainen
Emile E. Voest
Miklós Kásler
Frederik Falkenburg
Angelika Eggert
Bengt Jönsson
Douglas Hanahan
Mette Kalager
Péter Nagy
Caroline Dive
Manuel Heitor
Anton Berns
René Bernards
Ulrike Helbig
Eric Solary
Julio E. Celis
Carolina Espina
Klas Kärre
Pamela Kearns
Peter Strang
Françoise Meunier
Joachim Schüz
Alberto Bardelli
Jérôme Foucaud
Denis Lacombe
Yvonne Brandberg
Berns, Anton [0000-0003-2194-1988]
Baumann, Michael [0000-0002-9340-974X]
Espina, Carolina [0000-0001-6848-4687]
Schüz, Joachim [0000-0001-9687-2134]
Apollo - University of Cambridge Repository
Institut Català de la Salut
[Berns A] The Netherlands Cancer Institute, Amsterdam, the Netherlands. European Academy of Cancer Sciences, Stockholm, Sweden. [Ringborg U] European Academy of Cancer Sciences, Stockholm, Sweden. Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden. [Celis JE] European Academy of Cancer Sciences, Stockholm, Sweden. Danish Cancer Society Research Centre, Copenhagen, Denmark. [Heitor M] Ministry for Science, Technology and Higher Education, Lisbon, Portugal. [Aaronson NK] The Netherlands Cancer Institute, Amsterdam, the Netherlands. [Abou-Zeid N] Fondation ARC pour la recherche sur le cancer, Villejuif, France. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
Source :
Molecular Oncology, Vol 14, Iss 8, Pp 1589-1615 (2020), Molecular Oncology, Scientia
Publication Year :
2020

Abstract

A comprehensive cancer approach covering the entire research–care–prevention continuum can achieve a 10‐year cancer‐specific survival for 75% of patients diagnosed in EU member states with well‐developed health care by 2030. To ensure access to a critical mass of patient biological and technological resources, infrastructures for translational research, clinical and prevention trials, and outcomes research are needed. Here, we provide recommendations for achieving key targets and prioritize research areas.<br />A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research–care–prevention continuum has the potential to achieve in 2030 a 10‐year cancer‐specific survival for 75% of patients diagnosed in European Union (EU) member states with a well‐developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high‐quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science‐driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC‐like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long‐term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans‐border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence‐based advice.

Details

Language :
English
Database :
OpenAIRE
Journal :
Molecular Oncology, Vol 14, Iss 8, Pp 1589-1615 (2020), Molecular Oncology, Scientia
Accession number :
edsair.doi.dedup.....da36c5f61c979213e70bcb1ed8a224c5